<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03718143</url>
  </required_header>
  <id_info>
    <org_study_id>17-01816</org_study_id>
    <nct_id>NCT03718143</nct_id>
  </id_info>
  <brief_title>AZD1775 in Advanced Acute Myeloid Leukemia, Myelodysplastic Syndrome and Myelofibrosis</brief_title>
  <official_title>A Phase 2 Study of WEE1 Inhibition and AZD1775 Alone or Combined With Cytarabine in Patients With Advanced Acute Myeloid Leukemia, Myelodysplastic Syndrome and Myelofibrosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NYU Langone Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NYU Langone Health</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A phase II study testing the efficacy of combined AZD1775 with AraC or single agent activity
      of AZD1775 in three arms: Arm A has subjects age 60 years or older who are newly diagnosed
      with AML receiving the combination of the drugs; Arm B has subjects who are have
      relapsed/refractory AML and HMA failure MDS patients being allocated to either the
      combination Arm B or single agent AZD1775 Arm C.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A phase II study testing the clinical efficacy of combined AZD1775 with AraC or single agent
      activity of AZD1775 in three patient strata: Elderly(&gt; 60 years) newly diagnosed AML patients
      (Arm A) will only receive the combination; whereas relapsed/refractory AML patients and HMA
      failure MDS patients will be allocated to either the combination (Arm B) or single agent
      AZD1775 (Arm C). The study will have a run in safety cohort of six patients in each of the
      three arms to determine the safe use of combined AraC /AZD1775 or single agent AZD1775 in the
      patient populations. This will be followed by an expansion phase of up to 20 and 21 eligible
      patients in each arm respectively where elderly patients with newly diagnosed AML will
      receive a combination of AZD1775 and AraC (Arm A) while patients with relapsed or refractory
      AML or HMA failure MDS will be allocated to receive either AZD1775 with AraC (Arm B) or
      AZD1775 alone (Arm C). An early toxicity check will be conducted to determine safety and
      tolerability. If indicated, dose levels will be reduced. The study will continue to enroll
      the rest of the patients at the tolerated dose.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Safety concerns
  </why_stopped>
  <start_date type="Actual">May 8, 2019</start_date>
  <completion_date type="Actual">September 27, 2019</completion_date>
  <primary_completion_date type="Actual">September 27, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Complete Remission (CR) Rate</measure>
    <time_frame>4 months</time_frame>
    <description>Less than 5% blasts in a non-hypocellular marrow with a granulocyte count ≥ 1.0, and a platelets count of ≥ 100 with complete resolution of extramedullary disease and absence of peripheral blood blasts.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incomplete Measure of Complete Remission (CRi)</measure>
    <time_frame>4 months</time_frame>
    <description>is called if patient meets all CR criteria except for residual neutropenia (ANC&lt;1 x109/L) or thrombocytopenia (platelets&lt;100 x109/L)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete Cytogenetic Remission (CCyR)</measure>
    <time_frame>4 Months</time_frame>
    <description>The absence of chromosome abnormalities (if present at diagnosis) on conventional cytogenetic study using G-banding (at least 10 metaphases present).</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>Myelofibroses</condition>
  <condition>Acute Myeloid Leukemia</condition>
  <condition>Myelodysplastic Syndromes</condition>
  <arm_group>
    <arm_group_label>Arm A: Elderly Newly diagnosed AML</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Combination AZD1775 with AraC
Elderly, newly diagnosed AML</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B:Relapsed AML and MDS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Combination AZD1775 with AraC
Relapsed/Refractory AML &amp; HMA failure AML/ MDS</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm C: Relapsed AML, MDS and MF</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>AZD1775 only
Relapsed/Refractory AML &amp; HMA failure AML/ MDS and Relapsed/Refractory Primary &amp; Secondary MF</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Combination AZD1775 with AraC</intervention_name>
    <description>AZD1775 days 1-5 &amp; 8-12 AraC days 1-5 &amp; 8-12</description>
    <arm_group_label>Arm A: Elderly Newly diagnosed AML</arm_group_label>
    <arm_group_label>Arm B:Relapsed AML and MDS</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZD1775 only</intervention_name>
    <description>AZD1775 days 1-5 &amp; 8-12</description>
    <arm_group_label>Arm C: Relapsed AML, MDS and MF</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion:

        Inclusion Criteria

          -  Dose escalation part of trial for combined AraC + AZD1775 (Arm A)

          -  untreated elderly (&gt;60 years) AML if in the poor-risk cytogenetic group (please
             reference Appendix V).

          -  untreated elderly (&gt;60 years) AML if in the intermediate and poor-risk cytogenetic
             group (please reference Appendix V)

          -  relapsed or refractory AML (≥ 18 years)

          -  any MDS (≥ 18 years) having failed or been intolerant to prior hypomethylating agent
             (HMA) treatment.

          -  Failure is defined as any disease progression while on HMA, relapse after HMA
             treatment or no response after 4 cycles of 5-Azacitidine or decitabine

          -  Patients with isolated 5q-/5q- syndrome must have failed, not tolerated, or progressed
             on lenalidomide in addition to having failed or been intolerant to HMA treatment.

          -  advanced progressive MF, defined as intermediate and high risk primary and secondary
             MF, or any other MF failed or intolerant to JAK2 inhibitor therapy requiring medical
             therapy

          -  If appropriate, patients can have failed other prior therapies for their disease (i.e.
             JAK2 inhibitor, interferon, hydroxyurea or IMIDs). Patients may have failed more than
             one JAK2 inhibitor and JAK2 inhibitor must not have been the most recent treatment
             (e.g. other therapies as last therapy prior to study given after failure of previous
             JAK2 inhibitor).

          -  Failure/ intolerance of Ruxolitinib

          -  The following laboratory values obtained 7 days prior to registration.

          -  Total bilirubin ≤ 1.5 mg/dL (except Gilbert's syndrome or known hemolysis or leukemic
             infiltration)

          -  AST (SGOT) and ALT (SGPT) ≤ 2.5 x Upper Limit normal (ULN) or &lt; 5 x ULN if organ
             involvement

          -  Alkaline Phosphatase &lt; 5 x ULN - Serum creatinine ≤1.5 x ULN, or measured creatinine
             clearance (CrCl) ≥45 mL/min as calculated by the Cockcroft-Gault method (confirmation
             of creatinine clearance is only required when creatinine is &gt;1.5 x institutional ULN)
             CrCl (glomerular filtration rate [GFR]) = (140-age) x (weight/kg) x Fa (72 x serum
             creatinine mg/dL) a where F= 0.85 for females and F=1 for males

          -  ECOG Performance Status (PS) 0, 1 (Appendix I).

          -  Ability to provide informed written consent and be able to adhere to the study visit
             schedule and other protocol requirements.

          -  Willing to return to enrolling institution for follow-up (during the Active Monitoring
             Phase of the study).

          -  Willing to provide blood and bone marrow aspirate samples for correlative research
             purposes

          -  Negative serum pregnancy test done ≤7 days prior to registration, for women of
             childbearing potential only.

          -  Female patients who are not of child-bearing potential and fertile females of
             childbearing potential

          -  Male patients should be willing to abstain or use barrier contraception (i.e.,
             condoms) for the duration of the study drug exposure and for 3 months after study
             treatment discontinuation.

          -  Patients who have undergone stem cell transplantation (SCT), autologous or allogeneic,
             are eligible provided that they are &gt; 60 days from stem cell infusion, have GVHD &lt;
             grade 1 and are off immunosuppressive agents for &gt; 28 days at time of registration.

        Exclusion:

          -  AML patients who are suitable for and willing to receive intensive chemotherapy

          -  Any of the following because this study involves an investigational agent whose
             genotoxic, mutagenic and teratogenic effects on the developing fetus and newborn are
             unknown:

               -  Pregnant women

               -  Nursing women

               -  Men or women of childbearing potential who are unwilling to employ adequate
                  contraception

          -  Subject has had prescription or non-prescription drugs or other products known to be
             sensitive CYP3A4 substrates or CYP3A4 substrates

          -  The preferred azole anti-fungal medication is Fluconazole (alternatively Posaconazole)
             which can be given during treatment with AZD1775 (section 9.5).

          -  Pateints may not be on an inhibitor of BCRP as outlined in Appendix VI.

          -  Not willing to avoid grapefruit, grapefruit juices, grapefruit hybrids, Seville
             oranges, pummelos, and exotic citrus fruits from 7 days prior to the dose of study
             medication

          -  Mean resting corrected QTc interval using the Fridericia formula (QTcF) &gt;450 msec/male
             and &gt;470 msec/female (as calculated per institutional standards) obtained from 3
             electrocardiograms (ECGs) 2-5 minutes apart at study entry, or congenital long QT
             syndrome

          -  Herbal preparations/medications
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>NYU Langone Health</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>October 8, 2018</study_first_submitted>
  <study_first_submitted_qc>October 22, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 24, 2018</study_first_posted>
  <results_first_submitted>May 7, 2020</results_first_submitted>
  <results_first_submitted_qc>May 7, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">May 21, 2020</results_first_posted>
  <last_update_submitted>May 20, 2020</last_update_submitted>
  <last_update_submitted_qc>May 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Primary Myelofibrosis</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>MK-1775</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Individual participant data that underlie the results reported in this article, after deidentification (text, tables, figures, and appendices). Upon reasonable request.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_time_frame>Beginning 9 months and ending 36 months following article publication or as required by a condition of awards and agreements supporting the research.</ipd_time_frame>
    <ipd_access_criteria>The investigator who proposed to use the data.</ipd_access_criteria>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>August 23, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/43/NCT03718143/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Arm A: Elderly Newly Diagnosed AML</title>
          <description>Combination AZD1775 with AraC
Elderly, newly diagnosed AML
Combination AZD1775 with AraC: AZD1775 days 1-5 &amp; 8-12 AraC days 1-5 &amp; 8-12</description>
        </group>
        <group group_id="P2">
          <title>Arm B:Relapsed AML and MDS</title>
          <description>Combination AZD1775 with AraC
Relapsed/Refractory AML &amp; HMA failure AML/ MDS
Combination AZD1775 with AraC: AZD1775 days 1-5 &amp; 8-12 AraC days 1-5 &amp; 8-12</description>
        </group>
        <group group_id="P3">
          <title>Arm C: Relapsed AML, MDS and MF</title>
          <description>AZD1775 only
Relapsed/Refractory AML &amp; HMA failure AML/ MDS and Relapsed/Refractory Primary &amp; Secondary MF
AZD1775 only: AZD1775 days 1-5 &amp; 8-12</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Progression of Disease</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal of Informed Consent</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Total Participants</title>
          <description>Participants from all 3 arms:
Arm A: Elderly Newly Diagnosed AML Arm B: Relapsed AML and MDS Arm C: Relapsed AML, MDS, and MF
Baseline information cannot be separated by diagnoses due to data privacy reasons</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="6"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Complete Remission (CR) Rate</title>
        <description>Less than 5% blasts in a non-hypocellular marrow with a granulocyte count ≥ 1.0, and a platelets count of ≥ 100 with complete resolution of extramedullary disease and absence of peripheral blood blasts.</description>
        <time_frame>4 months</time_frame>
        <population>No data was collected for this outcome measure due to early termination of study.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A: Elderly Newly Diagnosed AML</title>
            <description>Combination AZD1775 with AraC
Elderly, newly diagnosed AML
Combination AZD1775 with AraC: AZD1775 days 1-5 &amp; 8-12 AraC days 1-5 &amp; 8-12</description>
          </group>
          <group group_id="O2">
            <title>Arm B:Relapsed AML and MDS</title>
            <description>Combination AZD1775 with AraC
Relapsed/Refractory AML &amp; HMA failure AML/ MDS
Combination AZD1775 with AraC: AZD1775 days 1-5 &amp; 8-12 AraC days 1-5 &amp; 8-12</description>
          </group>
          <group group_id="O3">
            <title>Arm C: Relapsed AML, MDS and MF</title>
            <description>AZD1775 only
Relapsed/Refractory AML &amp; HMA failure AML/ MDS and Relapsed/Refractory Primary &amp; Secondary MF
AZD1775 only: AZD1775 days 1-5 &amp; 8-12</description>
          </group>
        </group_list>
        <measure>
          <title>Complete Remission (CR) Rate</title>
          <description>Less than 5% blasts in a non-hypocellular marrow with a granulocyte count ≥ 1.0, and a platelets count of ≥ 100 with complete resolution of extramedullary disease and absence of peripheral blood blasts.</description>
          <population>No data was collected for this outcome measure due to early termination of study.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incomplete Measure of Complete Remission (CRi)</title>
        <description>is called if patient meets all CR criteria except for residual neutropenia (ANC&lt;1 x109/L) or thrombocytopenia (platelets&lt;100 x109/L)</description>
        <time_frame>4 months</time_frame>
        <population>No data was collected for this outcome measure due to early termination of study.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A: Elderly Newly Diagnosed AML</title>
            <description>Combination AZD1775 with AraC
Elderly, newly diagnosed AML
Combination AZD1775 with AraC: AZD1775 days 1-5 &amp; 8-12 AraC days 1-5 &amp; 8-12</description>
          </group>
          <group group_id="O2">
            <title>Arm B:Relapsed AML and MDS</title>
            <description>Combination AZD1775 with AraC
Relapsed/Refractory AML &amp; HMA failure AML/ MDS
Combination AZD1775 with AraC: AZD1775 days 1-5 &amp; 8-12 AraC days 1-5 &amp; 8-12</description>
          </group>
          <group group_id="O3">
            <title>Arm C: Relapsed AML, MDS and MF</title>
            <description>AZD1775 only
Relapsed/Refractory AML &amp; HMA failure AML/ MDS and Relapsed/Refractory Primary &amp; Secondary MF
AZD1775 only: AZD1775 days 1-5 &amp; 8-12</description>
          </group>
        </group_list>
        <measure>
          <title>Incomplete Measure of Complete Remission (CRi)</title>
          <description>is called if patient meets all CR criteria except for residual neutropenia (ANC&lt;1 x109/L) or thrombocytopenia (platelets&lt;100 x109/L)</description>
          <population>No data was collected for this outcome measure due to early termination of study.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Complete Cytogenetic Remission (CCyR)</title>
        <description>The absence of chromosome abnormalities (if present at diagnosis) on conventional cytogenetic study using G-banding (at least 10 metaphases present).</description>
        <time_frame>4 Months</time_frame>
        <population>No data was collected for this outcome measure due to early termination of study.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A: Elderly Newly Diagnosed AML</title>
            <description>Combination AZD1775 with AraC
Elderly, newly diagnosed AML
Combination AZD1775 with AraC: AZD1775 days 1-5 &amp; 8-12 AraC days 1-5 &amp; 8-12</description>
          </group>
          <group group_id="O2">
            <title>Arm B:Relapsed AML and MDS</title>
            <description>Combination AZD1775 with AraC
Relapsed/Refractory AML &amp; HMA failure AML/ MDS
Combination AZD1775 with AraC: AZD1775 days 1-5 &amp; 8-12 AraC days 1-5 &amp; 8-12</description>
          </group>
          <group group_id="O3">
            <title>Arm C: Relapsed AML, MDS and MF</title>
            <description>AZD1775 only
Relapsed/Refractory AML &amp; HMA failure AML/ MDS and Relapsed/Refractory Primary &amp; Secondary MF
AZD1775 only: AZD1775 days 1-5 &amp; 8-12</description>
          </group>
        </group_list>
        <measure>
          <title>Complete Cytogenetic Remission (CCyR)</title>
          <description>The absence of chromosome abnormalities (if present at diagnosis) on conventional cytogenetic study using G-banding (at least 10 metaphases present).</description>
          <population>No data was collected for this outcome measure due to early termination of study.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>4 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Arm A: Elderly Newly Diagnosed AML</title>
          <description>Combination AZD1775 with AraC
Elderly, newly diagnosed AML
Combination AZD1775 with AraC: AZD1775 days 1-5 &amp; 8-12 AraC days 1-5 &amp; 8-12</description>
        </group>
        <group group_id="E2">
          <title>Arm B:Relapsed AML and MDS</title>
          <description>Combination AZD1775 with AraC
Relapsed/Refractory AML &amp; HMA failure AML/ MDS
Combination AZD1775 with AraC: AZD1775 days 1-5 &amp; 8-12 AraC days 1-5 &amp; 8-12</description>
        </group>
        <group group_id="E3">
          <title>Arm C: Relapsed AML, MDS and MF</title>
          <description>AZD1775 only
Relapsed/Refractory AML &amp; HMA failure AML/ MDS and Relapsed/Refractory Primary &amp; Secondary MF
AZD1775 only: AZD1775 days 1-5 &amp; 8-12</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Progression of Disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Rachael Keller, Sr. Regulatory Specialist</name_or_title>
      <organization>NYU Langone Health - PCC CTO</organization>
      <phone>929-455-2453</phone>
      <email>Rachael.Keller@nyulangone.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

